Recent studies in pharmacology have focused on liver enzyme activity in the biotransformation of drugs. Among the 34 hepatic cytochrome P450 isoenzymes identifed to date, several have been found to be important in the metabolism of many psychoactive drugs and other agents. This article describes the role of cytochrome P450 isoenzymes in drug metabolism and potential drug-drug interactions and addresses nursing issues related to assessment, treatment, and patient education and safety.
Carson, S.W. (1996). Pharmacokinetic and pharmacodynamic drug interactions with polypharmacotherapy of treatment-resistant affective and obsessive-compulsive disorders. Psychopharmacology Bulletin, 32, 555-567.
3.
Daniel, H.I., & Edeki, T.I. (1996). Genetic polymorphism of Smephenytoin 4'-hydroxylation. Psychopharmacology Bulletin, 32, 219-230.
4.
DeVane, C.L. (1994). Pharmacogenetics and drug metabolism of newer antidepressant agents. Journal of Clinical Psychiatry, 55(Suppl 12), 38-45.
5.
DeVane, C.L., Spratt, E.G., & Sallee, F.R. (1997). Psychoactive drugdrug interactions in children, adolescents, and adults. Essential Psychopharmacology, 2(1), 33-50.
6.
DuPont, R.L. (1997). The pharmacology and drug interactions of the newer antidepressants. Essential Psychopharmacology, 2(1), 7-32.
7.
Ereshefsky, L. (1996). Drug-drug interactions involving antidepressants: Focus on venlafaxine. Journal of Clinical Psychopharmacology, 16 (Suppl. 2): 375-535.
8.
Ereshefsky, L., & Tollefson, G.D. (1995). Exploring the risks of drug interactions: SSRls and cytochrome. (Available from Pragmaton, 211 East Chicago Ave, Chicago, IL 60611)
9.
Glod, C.A. (1997). Antidepressants and the cytochrome P450 enzymes. Journal of the American Psychiatric Nurses Association, 2, 216-218.
10.
Hollander, A.A., van Rooij, J., Lentjes, G.W., Arbouw, F., van Bree, J.B., Schoemaker, R.C., van Es, L.A., van der Woude, F.J., & Cohen, A.F. (1995). The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients. Clinical Pharmacology and Therapeutics, 57, 318-324.
Keltner, N.L., Folks, D.G., Palmer, C.A., & Powers, R.E. (1998). Psychobiologicalfoundations of psychiatric care. St. Louis, MO: Mosby.
13.
Lin, K., Poland, R.E., Wan, Y., Smith, M.W., & Lesser, I.M. (1996). The evolving science of pharmacogenetics: Clinical and ethnic perspectives. Psychopharmacology Bulletin, 32, 205-217.
14.
Malseed, R.T., Goldstein, F.J., & Balkon, W. (1995). Pharmacology: Drug therapy and nursing considerations (4th ed.). Philadelphia: Lippincott.
15.
Michalets, E.L. (1998). Update: clinically significant cytochrome P 450 drug interactions. Pharmacotherapy, 18, 84-112.
16.
Nemeroff, C.B. (1994). Evolutionary trends in the pharmacotherapeutic management of depression. Journal of Clinical Psychiatry, 55(Suppl. 12), 3-15.
17.
Nemeroff, C.B., DeVane, C.L., & Pollock, B.G. (1996). Newer antidepressants and the cytochrome P450 system. American Journal of Psychiatry, 153, 311-320.
18.
Pollock, B.G. (1997). The endocrine-treatment interface: Gender differences in psychotropic drug metabolism. Psychopharmacology Bulletin, 33, 235-240.
19.
Shen, W.W., & Lin, K. (1991). Cytochrome P450 monooxygenases and interactions of psychotropic drugs. International Journal of Psychiatry in Medicine, 21, 47-56.
20.
Slaughter, R.L., & Edwards, D.J. (1995). Recent advances: The cytochrome P450 enzymes. The Annals of Pbarmacotherapy, 29, 619-624.
21.
Wheatley, M.D., van Moffaert, M., Timmerman, L., & Kremer, C.M.E. (1998). Mirtazapine: Efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Journal of Clinical Psychiatry, 59, 306-312.
22.
Yonkers, K.A., Kando, J.C., & Hamilton, J. (1996). Gender issues in psychopharmacologic treatment. Essential Psychopharmacology, 1(1), 54-69.
